The E2F transcription factor was originally identified as a cellular DNA-binding protein that recognized and bound to two adjacent elements in the adenovirus E2 promoter, sites that were critical for ElA-mediated activation of E2 transcription (31) . Subsequent studies demonstrated that a product of the adenovirus E4 gene, a 19-kDa polypeptide, interacted with E2F and in so doing facilitated cooperative binding to the adjacent E2F sites (21, 22, 27, 41, 48) . More recent work has shown that in most cell types, E2F is normally complexed to other cellular proteins and that these complexes cannot bind the E4 protein (1) . The adenovirus ElA protein is capable of disrupting these complexes, thus allowing E4 to interact with E2F and form a stable complex on the E2 promoter (1) .
The identification of the components of these E2F complexes has shed considerable light on the normal cellular role of E2F and the role of ElA, as well as other DNA tumor virus oncoproteins, in stimulating transcription and promoting oncogenesis (for a review, see reference 43) . All of the proteins found in association with E2F were previously identified as proteins interacting with ElA, T antigen, and E7. These include the retinoblastoma gene product [2, 4, 8, 9] , the Rb-related p107 protein (6, 14, 44, 54) , and the cell cycle regulatory proteins cyclin A and cdk2 (3, 6, 14, 40, 44 ). It appears that as a consequence of the interaction of ElA with these proteins, the E2F complexes are disrupted and E2F is released.
A variety of experiments have now shown that the interaction of Rb with E2F inhibits the transcriptional activating capacity of E2F (12, 20, 25, 60) or in fact creates a dominant transcriptional repressor (57) . Targets for transcriptional activation by E2F appear to include genes that encode S phase activities, primarily enzymes involved in deoxynucleotide biosynthesis that are activated in late G1 of the cell * Corresponding author. growth response. These include genes encoding dihydrofolate reductase (5, 38, 55) , thymidine kinase (30) , and DNA polymerase alpha (45) . It appears that as free E2F accumulates during the latter part of G1 (40, 52, 54) , it can then serve to activate expression of these genes and facilitate entry into S phase. It appears that at least part of the oncogenic action of the DNA tumor virus proteins is to activate the expression of such genes in an otherwise quiescent cell, possibly to facilitate viral DNA replication. In the absence of a normal lytic viral infection, this action could contribute to a loss of normal cell growth regulation.
Although the Rb and p107 proteins exhibit sequence homology and possess common properties, including the ability to bind to E2F and to interact with the DNA tumor virus oncoproteins, the consequence of the interaction with E2F may be quite different. At the present time, the interaction of Rb with E2F is most easily viewed as regulating the transcriptional activity of E2F, and this correlates with the growth-suppressing function of Rb (46, 47) . Although this activity may also be a consequence of the p107 interaction with E2F, it is likely more complex. Because of the ability of p107 to interact with cyclin A and the association of cyclin A with the p33 cdk2 kinase, the E2F complex that accumulates during S phase generates a cyclin-dependent protein kinase that possesses sequence-specific DNA-binding activity (6, 14, 44, 54) . It is thus possible that E2F may serve a quite different role in this context, possibly independent of its role as a transcription factor. Regardless, it is quite possible that the interaction of Rb with E2F could be different from the interaction of p107 with E2F. The recent isolation of a clone termed E2F1 (24, 29, Cll ATG AAG CGG AGG CTG G-3'   E113 .  5'-GCT CGG GGC AGA GGC GAA TTCCCA GGA AAA GGT GTG-3'  E120 .   5'-CCA GGA AAA GGT GTG GAA TTC; CCG GGG GAG AAG TCA-3'   E132 .   5'-CGC TAT GAG ACC TCA GAA&fC CTG ACC ACC AAG CGC-3'   E138 . 5'-CTG ACC ACC AAG CGC GAA TrC GAG CTG CTG AGC CAC-3' E177 .
5'-AAC GTC ClT GAG GGC GAATTC CTC ATT GCC AAG AAG-3' E206 .
5'-GGA CGG ClT GAG GGG GAA&TC CAG GAC CTC CGA CAG-3' E220 .
5'-GAG AGC GAG CAG CAG ,GAA TC CAC CTG ATG AAT ATC-3' B358 .
5'-CIG GAG CAA GAA CCGG GATACITCC CGG ATG GGC AGC-3' a The restriction sites generated are underlined.
yielded results consistent with the initial findings (53) . The DNA-binding domain appears from sequence analysis to suggest a basic helix-loop-helix motif, and the transcription activation domain exhibits properties characteristic of the acidic class of activation domains. These studies identified sequences essential for Rb binding within the acidic activation domain. This Rb-binding domain lacks the characteristic Leu-X-Cys-X-Glu motif found in the viral oncoproteins ElA, T antigen, and E7 (16) as well as other cellular proteins that bind Rb (13) .
To more fully understand the nature of the regulation of E2F activity as mediated by cellular regulatory proteins Rb and p107, as well as by the adenovirus E4 protein, we generated a series of E2F1 cDNAs in which various amino acid residues were altered in order to define the functional properties of E2F with respect to control by these cellular and viral regulatory proteins. (32, 61) . E2F1 derivatives were identified by direct sequencing or detected first by restriction digests and confirmed by subsequent sequencing (51) . Mutants generated in the M13 vector were subcloned into pCMV-E2F1 for expression of the E2F1 variants. Some E2F1 mutants were cloned full-length into a pGEX-2T vector modified to contain an XbaI cloning site to allow expression as glutathione S-transferase (GST)-E2F1 fusion proteins in Escherichia coli.
MATERIALS AND METHODS
The oligonucleotides used to generate mutations within the N-terminal portion of the E2F1 polypeptide are listed in Table 1 . The oligonucleotides used to generate mutations within the C-terminal acidic domain are listed in Table 2 .
The E2F1Fs4O9 frameshift mutant has been previously described (28) . The E2F1 mutant, GS393, in which E2F1 Gly-393 is replaced by a serine residue represents an E2F1 polymorphism identified in established human cell lines and in human tissue samples (10) . E2Fldl42022, which deletes E2F1 amino acids 420, 421, and 422, was constructed by replacing the wild-type XhooI-XbaI fragment of pCMV-E2F1 with an appropriate double-stranded oligonucleotide. Various E2F1 deletion mutants were constructed by using the artificial restriction sites generated.
Transfection assays and cell culture. The C-33A (Rb-deficient) cervical carcinoma cell line and the T98G human glioblastoma cell line (obtained from the American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). Transfections were carried out by calcium phosphate coprecipitation. All transfections utilized 100-mm plates, and each plate received 5 ,ug of pE2wt-CAT as the reporter gene (36), 2 ,ug of RSV-3-gal (37) as an internal control, and carrier DNA to a total of 20 1±g (Specialty Media, Inc.). The DNA concentrations used for the E2F1, E4, Rb, and p107 expression plasmids were each independently optimized by titration experiments for each of the two cell lines used. The DNA concentrations used represent the minimal concentrations which achieve maximum biological activity.
To evaluate transcriptional activation and coactivation with E4, T98G cells were transfected with 100 ng of pCMV-E2F1 (or a variant thereof) and 100 ng of an E4-expressing plasmid (41) . In order to minimize the level of endogenous E2F activity and thus improve the sensitivity and specificity of this assay for exogenous E2F1, T98G cells were cultured in DMEM containing 0.1% FCS 16 h following transfection. This method was particularly important in E4 coactivation assays since added exogenous E4 coactivates with endogenous E2F (see Fig. 4A ). Cells were maintained in DMEM containing 0.1% FCS for 48 h after washing and were then harvested, and chloramphenicol acetyltransferase (CAT) and 3-galactosidase enzyme activities were determined (18, 39) . To evaluate p107 regulation of E2F1 variants, T98G cells were cotransfected with 100 ng of pCMV-E2F1 (or variant) and 2 ,ug of a plasmid expressing p107 amino acids 122 to 936 (52) . Cells were exposed to the DNA precipitates for 16 h, and then the DNA and media were removed and replaced with DMEM containing 10% FCS. Twenty-four hours later, the cells were harvested. To evaluate p107 or Rb regulation of E2F1 in the Rb-deficient cell line C-33A, cells were cotransfected with 200 ng of pCMV-E2F1 (or variant) and S ,g of p107-expressing plasmid or 8 ,ug of Rb-expressing plasmid (50) . Cells were exposed to the DNA precipitates for 16 h, and then the DNA and media were removed and replaced with DMEM containing 10% FCS. Forty-eight hours later, the cells were harvested.
DNA binding assays. A plasmid DNA fragment from the adenovirus E2 promoter containing two E2F recognition sites, but lacking a natural ATF site, was used as probe in DNA binding assays, which were performed essentially as described previously (59) . Each reaction mixture included 100 or 250 ng of GST-E2F1 fusion proteins expressed in E. coli and was affinity purified with glutathione-Sepharose 4B (Pharmacia) as described previously (56) .
Protein interaction assays. Approximately 1 ,ug of GST-Rb (amino acid residues 379 to 928) or GST-p107 (amino acid residues 252 to 936) already bound to 20 ,ul of glutathioneSepharose 4B beads (Pharmacia) was preincubated for 1 h at room temperature in 0.5 ml of 0.25% gelatin-50 mM KCl-50 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid [pH 7.0])-0.1 mM EDTA. Following this blocking step, the beads were collected by gentle centrifugation at room temperature and washed twice with 0.5 ml of the appropriate binding buffer containing 50 mM HEPES (pH 7.0), 0.1% Nonidet P-40, and 250 or 500 mM NaCl for p107 and Rb binding assays, respectively. The blocked and washed beads were finally suspended in 0.5 ml of binding buffer. E2F1 and variants were transcribed and translated directly from plasmid DNA in vitro by using the T7 TNT Coupled Transcription/Translation System (Promega) and were labeled with [35S]methionine. Ten microliters of in vitro-translated polypeptides was added to the 0.5-ml binding reaction mixtures, and binding was allowed to take place with gentle rocking at room temperature. After 30 min, the beads and any bound proteins were collected by gentle centrifugation. The beads were washed three times with binding buffer, and each wash included a 10-min rocking step. After the final wash, the beads were mixed with 20 ,ul of sodium dodecyl sulfate (SDS) sample loading buffer and boiled to denature and remove bound protein. The bound polypeptides were resolved by SDS-polyacrylamide gel electrophoresis (33) and were detected by fluorography.
RESULTS
Construction of E2F1 mutants. In order to define the elements of the E2F1 protein that are responsible for regulatory interactions with cellular and viral proteins, we have created a series of plasmids that expressed modified forms of the E2F1 gene product. The E2F1 cDNA was inserted into a vector, pcDNA I/amp (Stratagene), that allows in vivo expression of E2F1 from a cytomegalovirus promoter and in vitro transcription of E2F1 from a T7 promoter. The vector also allows the production of single-stranded DNA for high-efficiency mutagenesis. The series of E2F1 mutants constructed, as they relate to putative E2F1 functional domains, is shown in Fig. 1 . The E2F1 motifs that have been identified include a basic domain (amino acids [aa] 109 to 127), a helix-loop-helix domain (aa 128 to 181), a leucine repeat (aa 199 to 234), and a C-terminal acidic domain (aa 368 to 437). Each of these regions, as well as surrounding sequences, was targeted for site-specific mutagenesis. Artificial EcoRI sites were generated within the basic region, helix I, helix II, and the leucine repeat elements, resulting in substitutions of two amino acids. Mutations within the basic domain targeted basic residues, while mutations within the putative leucine repeat element targeted leucine residues. The C-terminal acidic domain was mutated primarily as single amino acid substitutions, with an emphasis on nonacidic residues within the previously defined 18-amino-acid Rb-binding domain (24) .
E2Fl-mediated transcriptional activation. The E2F1 derivatives described in Fig. 1 were characterized with respect to their ability to activate transcription of the adenovirus E2 promoter by using an assay described by Helin et al. (24) . As shown in Fig. 2 , the expression of the wild-type E2F1 protein activated transcription of the E2 promoter, elevating the level of CAT activity approximately 10-fold. As expected from previous work (24) , deletion of the N-terminal 88 amino acids (E2F1dll_88) had no measurable effect on activation of the E2 reporter, suggesting that this domain does not contribute significantly to DNA binding or to activation. Although we anticipated the involvement of the putative basic domain in DNA binding, on the basis of the basic helix-loophelix model for DNA-binding proteins, several substitutions within this region had only a minor effect on transcriptional function. An E2F derivative in which the basic region was deleted (dI113-120) exhibited reduced activity although approximately 40% of the wild-type transcriptional activation capacity was retained.
In contrast, amino acid substitutions within the putative helix-loop-helix motif abolished transcriptional activity. These included two amino acid substitutions at two positions in helix I (E2F1E132 and E2F1E138) and at a single position in helix II (E2F1E177) (Fig. 2A) . Direct DNA binding assays using GST fusion proteins demonstrated that these mutations of the helix-loop-helix domain destroyed the DNAbinding capacity, thus accounting for the loss of transcription activation. As shown in Fig. 3 NX-- or E220, had no effect on transcriptional activation. Indeed, even the deletion of this region (dI206-220) had only a marginal effect. Deletion of sequences downstream of the leucine repeat (residues 284 to 358) reduced transcription activity (Fig. 2B) . The loss of activity as a result of this deletion is not the result of simple loss of sequence, since an insertion of unrelated sequence did not restore activity (data not shown). Nevertheless, these sequences are not part of the previously defined DNA-binding domain (24) , and given the absence of any additional information as well as any recognizable motifs in these sequences, it is not possible to ascertain the significance of this result.
The effect of various mutations within the C-terminal domain on the transcriptional capacity of the E2F1 product is depicted in Fig. 2C and D. These sequences are clearly important for transcriptional activation, as indicated by the lack of activity of the E2F1FS409 mutant that results from a frameshift at position 409 within the acidic domain. Nevertheless, despite the importance of this C-terminal domain for activation, numerous amino acid substitutions were tolerated without a measurable loss of activity, similar to previous analyses of other such acidic activation domains (11, 26, 35) .
Coactivation of E2F1-mediated transcription by the adenovirus E4 protein requires the leucine repeat and the acidic domain. Previous experiments have shown that the 19-kDa product of the adenovirus E4 6/7 open reading frame interacts with the E2F transcription factor and in so doing stimulates cooperative binding to the adjacent E2F sites in the E2 promoter (21, 22, 27, 41, 48) . This cooperative binding results in the formation of a very stable DNA-protein complex and an enhanced level of transcription activation (48, 49) . The initial description of the E2F1 cDNA demonstrated that the product could bind to the E4 protein as well as to the Rb protein in in vitro assays (24, 29) . We sought to determine the relationship of the interactions of these cellular and viral regulatory proteins that target the E2F factor.
Transfection assays were employed to determine the effect of E4 expression on the various E2F1 mutants. As seen in Fig. 4A , transfection of an E4-expressing plasmid resulted in an activation of the E2-CAT reporter, whereas an E4 mutant that does not bind to partially purified E2F (42) did not stimulate E2-driven CAT expression. This activation presumably reflects the utilization of endogenous E2F by the E4 protein. Transfection of the E2F1 cDNA resulted in an activation similar to that achieved with E4, and cotransfection of a plasmid expressing the E4 19-kDa product together with E2F1 resulted in a further increase in the activation of the E2-CAT reporter plasmid. Because the net increase in activation as a result of cotransfection of E2F1 and E4 is considerably greater than the sum of E2F1 or E4 activation (E4 activation is due to endogenous E2F), we conclude that E2F1 and E4 are acting cooperatively.
Having established that E2F1 and E4 will coactivate E2 transcription, we next tested the series of E2F1 mutants for their ability to coactivate with E4 ( Fig. 4B to D) . We scored E4-mediated coactivation as an increase in net CAT activity in excess of the sum of E2F1 and E4 activation alone (indicated by the dashed line in Fig. 4 Regulation of E2F1 transcriptional activity by Rb and p107 can be distinguished by E2F1 mutation. Assays for the effect of either Rb or p107 on E2F1 activity revealed a distinct specificity compared with that of E4. As shown in Fig. 5 , cotransfection of a p107-expressing plasmid in T98G cells repressed the activity of E2F1, consistent with recent experiments that have shown an ability of p107 to inhibit E2F-dependent transcription (52) . In contrast to E4, the leucine repeat element was not required for p107-mediated repression and none of the single amino acid substitutions within the C-terminal domain had a strong effect on p107 repression. There were, however, several E2F1 mutants bearing multiple amino acid substitutions in the C-terminal domain, notably the E2F1d1420_422 and E2F1411/421 mutants, which reduced the inhibition by p107.
As shown in Fig. 6 , Rb could also repress the transcriptional activity of E2F1 in the Rb-deficient cell line C-33A, consistent with previous experiments that demonstrated an Rb repression of endogenous E2F-dependent transcription (12, 20, 25, 60 ). An Rb mutant lacking exon 21 sequences, however, did not reduce E2F1-mediated activation (data not shown). Like p107, the leucine repeat element of E2F1 was not required for regulation by Rb, as indicated by the E206 and E220 mutants as well as the deletion mutant d1206-220, since each of these mutants was efficiently repressed by Rb. In contrast to the results with p107, mutations in the C-terminal E2F1 domain had no effect on Rb-mediated repression. This difference is shown most clearly in the experiment for which the results are presented in Fig. 7 (Fig. 5C) , thus confirming the importance of these residues in p107 recognition. In VOL. 13, 1993 ,,f, k0 -ji. -6320 CRESS ET AL. addition to the five point mutants presented in Fig. 8B , we have tested each of the C-terminal domain mutants presented in Fig. 1B using this in vitro p107-binding assay (data not shown). We find that the mutants GS393, FP399, HP412, RA422, and FP429 which are repressed by p107 equivalent to that of the wild type (Fig. 5) , also bind with wild-type efficiency to GST-p107. The remaining mutants presented in Fig. 1B are all measurably reduced in p107 binding in vitro, and of these a subset (composed entirely of mutants affecting more than one amino acid) are to various extents resistant to p107 repression in vivo. These results suggest that this region of E2F1 directly contributes to the recognition of E2F1 by p107 and that regulation by p107 involves a direct contact in this region. Furthermore, it is apparent that certain residues within this region are more important for interaction with p107, perhaps because they are in direct contact with p107 in the complex.
DISCUSSION
The regulatory properties of E4, Rb, and p107 can be mediated through the E2F1 product. Experiments reported over the last several years have pointed to the important role of the E2F transcription factor in events of cellular growth control (43) . The isolation of a cDNA clone that encodes a protein with the properties of E2F (24, 29, 53) was an important step in allowing an analysis of the molecular basis for the regulatory interactions that control E2F activity. We have utilized the E2F1 clone to begin to define the structural and regulatory properties of E2F. This analysis demonstrates that the E2F1 product can be regulated by the overexpression of Rb, p107, and adenovirus E4 in transfection assays, suggesting that E2F1 may be naturally regulated by these factors and may be a component of previously defined cellular E2F activity. This conclusion must be qual- (A to C) Wild-type E2F1 (WT) and the indicated mutants were assayed for activation of the E2-CAT gene together with a p107-expressing plasmid. These experiments were performed in the T98G cell line. Cells were transfected, as described in Materials and Methods, with 100 ng of E2F1 cDNA with or without 2 ,g of wild-type p107. The data depicted represent the results of individual transfections. The CAT activity in cells transfected with wild-type E2F1 in the absence of p107 was normalized to 1. ified to the degree that overexpression as achieved in transfection assays obscures normal specificity. This is difficult to judge, but clearly the results do show that each of these regulatory proteins can regulate the E2F1 product.
The initial analyses of the E2F1 clone defined domains responsible for DNA binding, transcriptional activation, and Rb binding (24, 29) . Sequence analysis of the DNA-binding domain suggested that E2F1 belonged to the basic helixloop-helix class (29) . Consistent with the basic helix-loophelix model, we observed that mutations within the two putative helices abolish transcriptional activation in vivo and DNA binding in vitro. We found, however, that much of the putative basic region can be deleted without a great effect on specific DNA binding and the in vivo transcriptional activation capacity. This finding may suggest that the basic helixloop-helix model is insufficient to account for the experimental details and raises the possibility that a different mode of DNA binding may be operating.
Recent reports suggest the possibility of multiple E2F activities within the cell, since at least one additional cDNA (termed DP-1) that encodes a protein, distinct from the E2F1 product and with E2F DNA-binding properties, has been isolated (17) . Moreover, it appears that several others have also been identified (34) . This could suggest the existence of a family of products with similar activities, each with distinct functions within the cell, although it is possible that one or more of these products are partners for the E2F1 product, forming a heterodimeric complex that has the properties of E2F. This possibility would be consistent with the fact that the E2F1 product can respond to Rb, p107, and E4. Although we cannot rule out the possibility that the E2F1 product actually participates in only a subset of the regulatory events, and recent results suggest the possibility of distinct forms of E2F in association with Rb and p107 (15) mediated through E2F1. Furthermore, it is also now clear that overexpression of E2F1 can activate DNA synthesis in cells that would otherwise growth arrest and that microinjection of the E2F1 cDNA into quiescent cells can induce S phase entry (28) . Taken together, these observations suggest a central role for the E2F1 product in the control of cell cycle events.
Recognition of the E2F1 acidic domain by viral and cellular regulatory proteins. A large body of information regarding the control of E2F activity by the viral E4 protein as well as the cellular regulatory proteins Rb and p107 has now accumulated. Experiments utilizing extracts prepared from uninfected cells or virus-infected cells to assay for E2F DNAbinding activity have shown that the interaction of E4, Rb, or p107 with E2F appears to be mutually exclusive. For instance, although the E4 protein could interact with free E2F, it was blocked from an interaction with the E2F-Rb or the E2F-p1O7 complex (1) . Likewise, it would appear that p107 and Rb do not coexist in the same E2F complex detected in extracts of cells (6, 13) . The analyses described in this paper now show that the sequences in the E2F1 product that are required for these interactions do indeed overlap, each requiring the C-terminal acidic domain of E2F1, thus giving a structural basis for mutually exclusive interactions. Nevertheless, although there is overlap in the specificities, they are not identical. Although the interaction of each regulatory protein was dependent upon the C-terminal acidic domain of E2F1, the interactions were differentially affected by various amino acid substitutions within the E2F1 acidic domain.
The analysis of these mutations has shown that although none of the mutations affected Rb repression or in vitro binding to Rb, many of the mutants were to some degree defective in binding p107 in vitro and a subset of these were defective in p107 repression in vivo. It was also evident that the specificity of interactions involving E4 and p107 with A.
B.
iiiiilllli- (Fig. 5D) ; however, both coactivate with E4 (Fig. 4D) Finally, transfection assays have shown that the ability of E2F to stimulate transcription is correlated with the release of E2F from interactions with Rb and p107 (7, 12, 20, 25, 52, 60) . Clearly, these results are consistent with the finding that the interactions of Rb and p107 with E2F1 are dependent on sequences found within the transcription activation domain. In short, it is possible that these regulatory proteins may mask the activation domain of E2F1, preventing interactions with other components of the transcription machinery, including TBP. In this regard, it is interesting to note the recent description of sequence homologies between the Rb protein and the basal transcription factors TBP and TFIIB (19) . The domains of Rb that exhibit this homology are those required for binding to E2F. Perhaps Rb competes with factors such as TFIID and TFIIB for interaction with the acidic domain of E2F, thus preventing the formation of a functional transcription complex.
